# Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Study · id `cardio:ct-nct02150824` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02150824](<https://clinicaltrials.gov/study/NCT02150824>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02150824

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02150824. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02150824, source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)
- Start date: 2014-07 (registry gives no type) (ClinicalTrials.gov record NCT02150824, source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT02150824, source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02150824, source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02150824, source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02150824-2015-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): BI 187004
- Intervention (Drug): Placebo
- Intervention (Drug): BI 187004
- Intervention (Drug): BI 187004
- Intervention (Drug): BI 187004
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 0f551e1e4168cd62a4c4e58c99b0522c1f9d8611cb17c60b556ad8ae81aeebc6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
